Peripheral Arterial DiseaseNCT03052296
BIOLUX P-III SPAIN All-Comers Registry
An observational study of Peripheral Arterial Disease, run by Biotronik AG at 5 sites in Spain.
Trial summary
The purpose of the BIOLUX P-III Spain registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Balloon in the treatment of long atherosclerotic femoropoliteal artery lesions in daily clinical practice Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peripheral Arterial Disease
- What is being tested?
- Passeo-18 Lux DCB
- Type of treatment
- Medical device
- How many people
- 44 participants
- Where
- 5 sitesSpain
- Study dates
- 22 Mar 2017to 5 Nov 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The BIOLUX P-III SPAIN registry will include subjects from an all-comers patient population with all subjects requiring revascularization of long femoropopliteal artery lesions with the Passeo-18 Lux DCB
Who may be able to join
- Age ≥ 18 years or minimum age as required by local regulations
- Subject must be willing to sign a Patient Data Release Form (PDRF) or Patient Informed Consent (PIC) where applicable
- Subject classified as Rutherford class 4, 5 or 6
- TASC C or D lesion(s) in the femoropopliteal artery
- Lesion length > 15 cm suitable for endovascular treatment treated with or scheduled to be treated with the Passeo-18 Lux drug releasing balloon
Who cannot join
- Life expectancy ≤ 1 year
- Subject is currently participating in another investigational drug or device study that has not reached its primary endpoint yet.
- Subject is pregnant or planning to become pregnant during the course of the study.
- Rutherford class <4
- Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations).
- Intraprocedural decision not to proceed with the Passeo18 Lux DCB for any reason not related to the device (for instance blood flow limiting dissection after predilatation).
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Spain5 sites
Hospital Mataró
Barcelona
Hospital San Cecilio
Granada
Hospital Regional Universitario de Málaga
Málaga
Hospital Virgen de la Macarena
Seville
Hospital Clínico Lozano Blesa Zaragoza
Zaragoza
About this study
Official title: BIOTRONIK - A Prospective, National, Multi-centre, Post-market Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Long Femoropopliteal Artery Lesions - III SPAIN
The purpose of the BIOLUX P-III Spain registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Balloon in the treatment of long atherosclerotic femoropoliteal artery lesions in daily clinical practice
- Conditions
- Peripheral Arterial Disease
- Being tested
- Passeo-18 Lux DCB
- Medical subject headings
- Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Passeo-18 Lux DCBDevice
The endovascular procedure is conducted as per the local standard practice and device instruction for use
What is being measured
The primary outcome is the main question the study is designed to answer.
Freedom from Major Adverse Events (MAE)
A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)
Measured: 6 months
Freedom from clinically driven Target Lesion Revascularization (TLR)
Any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.)
Measured: 12 months
Secondary outcomes (12)
Freedom from clinically-driven target lesion revascularization (TLR)
Measured: 6 months
Freedom from clinically-driven target vessel revascularization (TVR)
Measured: 6 and 12 months
Primary Patency
defined as freedom from >50% restenosis in the target lesion as indicated by a duplex ultrasound peak systolic velocity ratio (PSVR) >2.5 or by visual assessment of an angiogram with no clinically driven re-intervention.
Measured: 12 months
Freedom from MAE
Composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven TLR
Measured: 12 months
Change in mean Ankle Brachial Index (ABI)
Thigh or toe brachial index (TBI) may be used / performed if ABI is inadequate
Measured: 6 and 12 months
Improvement in Rutherford classification compared to the pre-procedure Rutherford classification
Measured: 6 and 12 months
Amputation-free survival (AFS) including major, minor and overall AFS
Measured: 6 and 12 months
Pain score compared to the pre-procedure score
Measured: 6 and 12 months
Walking Impairment Questionnaire compared to the pre-procedure score
Measured: 6 and 12 months
Device success
Successful delivery, inflation, deflation, and retrieval of the Passeo-18 Lux DCB.
Measured: Immediately upon procedure
Technical success
Successful completion of the endovascular procedure and immediate morphological success with ≤ 50% residual diameter reduction of the treated lesion as determined by visual estimation.
Measured: Immediately upon procedure
Procedural success
Procedural success is technical and device success without the occurrence of any MAE (as defined in the protocol) during the hospital stay
Measured: Immediately upon discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2017
- Study start22 Mar 2017
- Primary completion5 Nov 2019
- Study completion5 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biotronik AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Miguel Angel de Gregorio, Principal investigator, Hospital Clínico and University of Zaragoza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03052296
- Sponsor's protocol ID
- C1603
- Status last verified
- Aug 2021
- First submitted
- 2 Feb 2017
- Last updated
- 5 Aug 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BIOTRONIK - A Prospective, National, Multi-centre, Post-market Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Long Femoropopliteal Artery Lesions - III SPAIN
- ClinicalTrials.gov ID
- NCT03052296
- Acronym / sponsor ID
- C1603
- Conditions
- Peripheral Arterial Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Biotronik AGIndustry (pharma, biotech, devices)
- Study start
- 22 Mar 2017 (actual)
- Primary completion
- 5 Nov 2019 (actual)
- Study completion
- 5 Nov 2019 (actual)
- First posted
- 14 Feb 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the BIOLUX P-III Spain registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Balloon in the treatment of long atherosclerotic femoropoliteal artery lesions in daily clinical practice
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The BIOLUX P-III SPAIN registry will include subjects from an all-comers patient population with all subjects requiring revascularization of long femoropopliteal artery lesions with the Passeo-18 Lux DCB
Key inclusion criteria (5 listed)
- Age ≥ 18 years or minimum age as required by local regulations
- Subject must be willing to sign a Patient Data Release Form (PDRF) or Patient Informed Consent (PIC) where applicable
- Subject classified as Rutherford class 4, 5 or 6
- TASC C or D lesion(s) in the femoropopliteal artery
- Lesion length > 15 cm suitable for endovascular treatment treated with or scheduled to be treated with the Passeo-18 Lux drug releasing balloon
Key exclusion criteria (6 listed)
- Life expectancy ≤ 1 year
- Subject is currently participating in another investigational drug or device study that has not reached its primary endpoint yet.
- Subject is pregnant or planning to become pregnant during the course of the study.
- Rutherford class <4
- Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Passeo-18 Lux DCBThe endovascular procedure is conducted as per the local standard practice and device instruction for use | Device | – |
Primary outcome
Freedom from Major Adverse Events (MAE)
Time frame: 6 months
A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)
Freedom from clinically driven Target Lesion Revascularization (TLR)
Time frame: 12 months
Any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.)
12 secondary outcomes
Freedom from clinically-driven target lesion revascularization (TLR)
Time frame: 6 months
Freedom from clinically-driven target vessel revascularization (TVR)
Time frame: 6 and 12 months
Primary Patency
Time frame: 12 months
Freedom from MAE
Time frame: 12 months
Change in mean Ankle Brachial Index (ABI)
Time frame: 6 and 12 months
Improvement in Rutherford classification compared to the pre-procedure Rutherford classification
Time frame: 6 and 12 months
Amputation-free survival (AFS) including major, minor and overall AFS
Time frame: 6 and 12 months
Pain score compared to the pre-procedure score
Time frame: 6 and 12 months
Walking Impairment Questionnaire compared to the pre-procedure score
Time frame: 6 and 12 months
Device success
Time frame: Immediately upon procedure
Technical success
Time frame: Immediately upon procedure
Procedural success
Time frame: Immediately upon discharge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2021.
- Individual participant dataSharing planned: No
Related trials for Peripheral Arterial Disease
Recruiting
Personalised Multicomponent Exercise Programme in Peripheral Arterial Disease
Peripheral Arterial Disease, Intermittent Claudication
Active, not recruitingPhase 1
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
Familial Erythromelalgia
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingPhase 1
A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions
Peripheral Arterial Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Miguel Angel de Gregorio principal investigator
Hospital Clínico and University of Zaragoza
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peripheral Arterial Disease, run by Biotronik AG at 5 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Freedom from Major Adverse Events (MAE) (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2021.